Education
About Us
Working with TipRanks
Follow Us
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
Top Page
Vivos Therapeutics
(NASDAQ:VVOS)
46Neutral
Positive Factors
Cost Control
Operating expenses in Q4 FY24 were down 21% yoy to $4.9 million, reflecting the company’s ongoing focus on cost control.
Regulatory Approval
FDA approval and new CPT codes highlight the company’s strong position as an alternative to CPAP, with regulatory coverage for all severities of OSA.
Negative Factors
Financing
The need for additional financing presents the likelihood of further dilutive financing in the next few quarters.
Vivos Therapeutics (VVOS) vs. S&P 500 (SPY)
Market Cap
$16.08M
Dividend YieldN/A
Average Volume (3M)86.22K
Price to Earnings (P/E)―
Beta (1Y)2.01
Revenue Growth8.91%
EPS Growth70.18%
CountryUS
Employees109
SectorHealthcare
Sector Strength58
IndustryMedical - Devices
Share Statistics
EPS (TTM)-3.10
Shares Outstanding5,889,520
10 Day Avg. Volume73,421
30 Day Avg. Volume86,221
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.48
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.85Price Target Upside114.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Vivos Therapeutics Business Overview & Revenue Model
Company DescriptionVivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
How the Company Makes MoneyVivos Therapeutics generates revenue primarily through the sale of its proprietary oral appliance system, known as The Vivos System. This system is sold to dentists and healthcare providers who are trained and certified by Vivos to diagnose and treat patients with OSA using their products. The company charges fees for training and certification programs for dentists, which is an additional revenue stream. Vivos also benefits from ongoing sales of appliance components and consumables required during patient treatment. Strategic partnerships and collaborations with dental and medical practices further enhance their market reach and contribute to their revenue growth.
Vivos Therapeutics Financial Statement Overview
Summary
Vivos Therapeutics faces significant financial challenges, with persistent losses and a reliance on external financing. Despite a positive gross profit margin, the company struggles to convert revenue into profit. The balance sheet indicates manageable leverage but low equity, while cash flow issues highlight the need for strategic improvements.Income Statement
Vivos Therapeutics has shown a slight improvement in revenue with a growth rate of 5.65% in the TTM period compared to the previous year. However, the company continues to face significant challenges in profitability, with negative net and EBIT margins at -86.15% and -84.73% respectively. Gross profit margin remains relatively high at 59.74%, indicating some operational efficiency. The consistent negative net income is a concern, suggesting ongoing financial difficulties.42
Neutral
Balance Sheet
The company's balance sheet reflects a mixed picture. The debt-to-equity ratio is relatively low at 0.21, indicating manageable leverage. However, the return on equity (ROE) remains negative at -163.98%, highlighting inefficiencies in generating profits from shareholders' equity. The equity ratio is moderate at 49.95%, suggesting a balanced approach between equity and liabilities but also underscoring a weak equity base.35
Negative
Cash Flow
Vivos Therapeutics has struggled with negative free cash flow, despite a slight improvement in free cash flow growth of 0.67%. The operating cash flow to net income ratio is slightly positive at 0.99, indicating that operational cash generation is close to net income levels, albeit both are negative. The company relies heavily on financing activities to support its cash flows, which could pose risks in the long term.38
Negative
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 13.80M | 16.02M | 16.89M | 13.07M | 11.39M | Gross Profit |
| 8.27M | 10.02M | 12.60M | 10.41M | 8.66M | EBIT |
| -17.30M | -25.03M | -19.47M | -8.71M | -10.58M | EBITDA |
| -16.68M | -24.36M | -19.54M | -11.24M | -9.87M | Net Income Common Stockholders |
| -13.58M | -22.66M | -20.29M | -8.82M | -10.89M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.64M | 3.52M | 24.03M | 18.21M | 469.35K | Total Assets |
| 10.73M | 13.72M | 33.69M | 25.33M | 7.55M | Total Debt |
| 2.00M | 2.41M | 1.63M | 1.29M | 3.71M | Net Debt |
| 352.00K | -1.11M | -22.40M | -16.92M | 3.24M | Total Liabilities |
| 10.32M | 8.92M | 8.15M | 8.41M | 10.49M | Stockholders Equity |
| 411.00K | 4.80M | 25.54M | 16.92M | -2.94M |
| Cash Flow | Free Cash Flow | |||
| -12.75M | -20.51M | -18.13M | -5.80M | -5.52M | Operating Cash Flow |
| -11.95M | -19.59M | -15.73M | -5.68M | -5.34M | Investing Cash Flow |
| -853.00K | -924.00K | -2.61M | -120.25K | 86.22K | Financing Cash Flow |
| 10.92M | 0.00 | 24.17M | 23.54M | 4.47M |
Vivos Therapeutics Technical Analysis
Negative
2.73
Price Trends
2.96
Negative
3.71
Negative
3.23
Negative
Market Momentum
-0.07
Negative
51.44
Neutral
84.56
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VVOS, the sentiment is Negative. The current price of 2.73 is above the 20-day moving average (MA) of 2.45, below the 50-day MA of 2.96, and below the 200-day MA of 3.23, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 51.44 is Neutral, neither overbought nor oversold. The STOCH value of 84.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VVOS.
Vivos Therapeutics Risk Analysis
Vivos Therapeutics disclosed 85 risk factors in its most recent earnings report. Vivos Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vivos Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.36B | 3.88 | -42.93% | 2.87% | 17.85% | 1.45% | |
46 Neutral | $16.08M | ― | -266.25% | ― | 8.91% | 70.18% | |
42 Neutral | $12.35M | ― | -53.65% | ― | -88.70% | -3.48% | |
40 Underperform | $13.56M | ― | -499.57% | ― | 22.15% | ― | |
34 Underperform | $13.36M | ― | 110.26% | ― | -2.99% | 59.87% | |
34 Underperform | $29.59M | ― | 5400.35% | ― | 122.22% | 79.08% |
* Healthcare Sector Average
Performance Comparison
VVOS
Vivos Therapeutics
2.73
0.10
3.80%
AXDX
Accelerate Diagnostics
0.53
-0.39
-42.39%
CODX
Co-Diagnostics
0.37
-0.84
-69.42%
PAVM
PAVmed
0.79
-1.28
-61.84%
BSGM
BioSig Technologies
1.37
-0.34
-19.88%
ADGM
Adagio Medical Holdings
1.26
-10.08
-88.89%
Vivos Therapeutics Earnings Call Summary
Earnings Call Date:Mar 31, 2025
(Q4-2024)
| % Change Since: -4.21%|
Next Earnings Date:May 19, 2025
Earnings Call Sentiment Positive
The earnings call presented a generally positive outlook for Vivos Therapeutics, highlighting significant revenue growth, strategic market expansion, and successful business model pivot. Despite some challenges with decreased VIP enrollment revenue and ongoing cash flow needs, the overall sentiment is optimistic due to strong financial backing and regulatory advancements.Q4-2024 Updates
Positive Updates
Revenue Increase and Cost Reduction
In 2024, Vivos Therapeutics increased product revenue by 26% and reduced operating expenses by 21%, resulting in a 35% reduction in operating loss.
Successful Market Expansion
Vivos expanded into the Middle East, gaining regulatory approvals and access to key markets including Dubai, UAE, Jordan, Bahrain, Lebanon, and Qatar. Demand in the region exceeded forecasts.
Strategic Shift in Business Model
Vivos pivoted its business model to partner with or acquire sleep testing clinics, aiming to be involved in the treatment decision process for OSA patients, which is expected to significantly increase revenue.
FDA Clearance for Severe OSA Treatment
FDA clearance was received for Vivos appliances to treat severe OSA, expanding their treatment capabilities and market credibility.
Significant Financial Backing
Raised approximately $17.9 million through multiple equity transactions, including a $7.5 million investment from New Seneca Partners.
High Conversion Rate in Pilot Programs
Pilot testing showed a 70% conversion rate of OSA patients to Vivos treatments, with an average revenue of $4,500 per case and contribution margins of up to 50%.
Negative Updates
Decreased VIP Enrollment Revenue
Service revenue decreased by $400,000 due to fewer VIP enrollments as part of the strategic shift in marketing and sales.
Cash Flow and Financing Needs
Despite positive financial results, Vivos is still using cash to fund operations and will require additional financing in the near term.
Company Guidance
During the 2024 fiscal year, Vivos Therapeutics reported a 26% increase in product revenue, reaching $7.9 million, while reducing operating expenses by 21%, leading to a 35% reduction in operating loss. The company sold 16,182 oral appliance arches, nearly doubling their sales compared to 2023. Additionally, Vivos expanded into the Middle East, gaining regulatory approvals in several regions and exceeding sales forecasts. The company raised approximately $17.9 million through equity transactions, including a $7.5 million investment from New Seneca Partners. Vivos also launched a new marketing and distribution strategy with Rebis Healthcare, focusing on profit-sharing alliances and acquisitions of sleep testing clinics, projecting roughly $38 million in annual revenue per 1,000 newly diagnosed OSA patients. The company expects significant growth in 2025, driven by their new strategic model, which has shown a 70% conversion rate of OSA patients choosing Vivos treatments, with average revenues of $4,500 per case and contribution margins up to 50%.Vivos Therapeutics Corporate Events
Executive/Board ChangesPrivate Placements and FinancingBusiness Operations and Strategy
Vivos Therapeutics Enters Market Offering Agreement with Wainwright
Neutral
Feb 14, 2025
On February 14, 2025, Vivos Therapeutics, Inc. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., allowing the company to sell shares of its common stock valued up to $3,328,881 through the Nasdaq Capital Market. This move is part of the company’s strategy to raise capital, with Wainwright acting as the sales agent under specific conditions and commission agreements. Additionally, the company amended employment agreements for its CEO and CFO, effective January 1, 2025, as part of an ongoing effort to align executive compensation with company goals.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.